Selective cyclooxygenase-2 inhibitor. Pharmacology and state of knowledge following commercial availability;Selektive cyclooxygenase-2-hemmer. Pharmakologie und kenntnisstand nach markteinführung

Schmerz

Volumn 15, Issue 3, 2001, Pages 207-219

  Schmidt, H ^a   Geisslinger, G ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB; ANALGESIC AGENT; ANTI INFLAMMATORY AGENTS, NON STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 3; CYCLOOXYGENASE-3; ISOENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

DRUG BINDING; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; PHARMACODYNAMICS; REVIEW; ENZYME SPECIFICITY; HUMAN; METABOLISM;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; HUMAN; ISOENZYMES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE; SUBSTRATE SPECIFICITY;

EID: 0034942803     PISSN: 0932433X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004820170026     Document Type: Review

References (72)

1. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis
2. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis
3. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
4. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomised controlled trial
5. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
6. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens
7. Mechanisms of action of anti-inflammatory drugs
8. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
9. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase
10. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids
11. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
12. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
13. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
14. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
15. Meloxicam: Influence on arachidonic acid metabolism. Part 1. In vitro findings
16. COX-2-specific inhibitors - The emergence of a new class of analgesic and anti-inflammatory drugs
17. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes
18. Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua
19. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors
20. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
21. Prostaglandins in macula densa function
22. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post surgical pain model
23. Specific COX-2 inhibitors: From bench to bedside
24. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs
25. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
26. New treatment options for Bartter's syndrome
27. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandinsynthase/cyclooxygenase gene
28. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
29. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs
30. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
31. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
32. Selective inhibition of cyclooxygenase-2 (COX-2) with MG-0966 (250 mg qd) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg qid or ibuprofen (IBU) 800 mg tid
33. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2-selective inhibitor
34. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding
35. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
36. The classification of cyclooxygenase inhibitors
37. Outcome of specific COX-2 inhibition in rheumatoid arthritis
38. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
39. Localization and regulation of cyclooxygenase-1 and -2 and neuronal nitric oxide synthase in mouse spinal cord
40. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice
41. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
42. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
43. Analgesic efficacy and plasma levels of a highly selective inhibitor of COX-2 (SC-58635; SC) in patients with post surgical dental pain
44. A study of the platelet effects of SC-58635, a novel COX-2-selective inhibitor
45. Acetaminophen inhibits spinal prostaglandin E2 release after peripheral noxious stimulation
46. The discovery and function of COX-2
47. Electrophysiological evidence for a spinal antinociceptive action of dipyrone
48. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils
49. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
50. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts
51. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
52. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
53. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)
54. Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn
55. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
56. Expression of cyclooxygenase-2 in human gastric carcinoma
57. A study of the mechanism of action of the mild analgesic dipyrone
58. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
59. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial
60. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
61. Purification and characterization of a novel, distinct isoform of endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles
62. Aspirin selectively inhibits prostaglandin production in human platelets
63. Prostaglandin endoperoxide H synthases-1 and -2
64. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: Implications for Alzheimer's disease
65. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers
66. Towards a better aspirin
67. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
68. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years
69. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
70. Expression ofa mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing